MoonLake's Sonelokimab Succeeds in Phase 3 Trial

Edgen Stock

·Mar 28 2026, 19:19

Share to

Share to

Copy link

Key Takeaways

MoonLake Immunotherapeutics announced highly positive long-term data for its inflammatory disease drug, Sonelokimab. The results from the pivotal Phase 3 trials substantially improve the drug's outlook for regulatory approval and commercial success, positioning the company for significant growth.

MoonLake Immunotherapeutics (MLTX) announced positive long-term Week 40 data from its Phase 3 VELA-1 and VELA-2 trials for its drug candidate, Sonelokimab.
The results, presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting, confirm the drug's efficacy for moderate-to-severe Hidradenitis Suppurativa.
This milestone significantly de-risks Sonelokimab's development path, boosting the probability of regulatory approval and future revenue streams.

MoonLake Confirms Long-Term Efficacy in Phase 3 Trials

On March 28, 2026, MoonLake Immunotherapeutics (NASDAQ: MLTX) announced pivotal long-term results from its Phase 3 program for Sonelokimab. The Week 40 data from the VELA-1 and VELA-2 trials demonstrated sustained efficacy in treating moderate-to-severe Hidradenitis Suppurativa, a chronic and debilitating inflammatory skin disease. The company confirmed the findings were presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting, a key event for the specialty.

Positive Data Boosts Sonelokimab's Path to Market

The successful Week 40 data marks a critical de-risking event for MoonLake and its lead drug candidate. For investors, demonstrating long-term safety and effectiveness in a Phase 3 trial is a crucial step that significantly increases the probability of gaining regulatory approval and moving towards commercialization. The results solidify Sonelokimab's potential as a next-level therapy and pave a clearer path to future revenue, likely prompting a positive revaluation of the company's stock as it moves closer to tapping into the inflammatory disease market.